Published in Health and Medicine Week, October 18th, 2004
"Our lead product candidate, edifoligide (E2F Decoy) is tracking well, and top-line results are expected for our phase III studies in peripheral bypass graft by the end of this year and coronary artery bypass graft in early 2005. We are, therefore, able to expand our focus to bringing our second and third transcription factor decoys to the clinic, thereby continuing to build long-term value for our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.